

amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council for Human Genome Research.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council for Human Genome Research.

Date: May 20–21, 2002.

Open: May 20, 2002, 8:30 a.m. to 12:30 p.m.

Agenda: Discussion of NHGRI events and program priorities.

Place: Holiday Inn, 8777 Georgia Avenue, Silver Spring, MD 20910.

Closed: May 20, 2002, 1:30 p.m. to adjournment on May 21, 2002.

Agenda: To review and evaluate grant applications and/or proposals.

Place: Holiday Inn, 8777 Georgia Avenue, Silver Spring, MD 20910.

Contact Person: Elke Jordan, PhD, Deputy Director, National Human Genome Research Institute, National Institutes of Health, PHS, DHHS, 31 Center Drive, Building 31, Room 4B09, Bethesda, MD 20892, 301–496–0844. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS)

Dated: April 18, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02–10114 Filed 4–24–02; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse and Alcoholism; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the

National Advisory Council on Alcohol Abuse and Alcoholism

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council on Alcohol Abuse and Alcoholism.

Date: June 5–6, 2002.

Closed: June 5, 2002, 7 p.m. to 9 p.m.

Agenda: To review and evaluate grant applications and/or proposals.

Place: Bethesda Marriott Hotel, 5151 Pooks Hill Road, Bethesda, MD 20814.

Open: June 6, 2002, 8:30 a.m. to 4 p.m.

Agenda: Program documents.

Place: 45 Center Drive, Natcher Building, Conference Room E1/2, Bethesda, MD 20892.

Contact Person: Kenneth R. Warren, PHD, Director, Office of Scientific Affairs, National Advisory Council on Alcohol Abuse and Alcoholism, National Institutes of Health, Wilco Building, Suite 409, 6000 Executive Boulevard, Bethesda, MD 20892–7003, 301–443–4375, kwarren@niaaa.nih.gov

Information is also available on the Institute's/Center's home page: silk.nih.gov/silk/niaaa1/about/roster.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants, National Institutes of Health, HHS)

Dated: April 18, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02–10115 Filed 4–24–02; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Targeted Gene Expression for the Treatment of Cancer, Bone Metastasis and Diabetes

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 (c)(1) and 37 CFR 404.7 (a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in the Provisional Patent Application No. 60/024,213, filed 8/15/96, converted to PCT (PCT/US97/15270) filed on 8/14/97 entitled “Spatially and Temporal Control of Gene Expression Protein Promoter in Combination with Local Heat” to Gene Control S.A., a non-U.S. corporation located at 9, rue Boissonnas CH 1211 Geneva 24, Switzerland. The patent rights of this invention have been assigned to the United States of America. The proposed field of use may be limited to targeted gene expression, for the treatment of cancer, bone metastasis and diabetes.

DATES: Only written comments and/or applications for a license, received by the NIH Office of Technology Transfer on or before June 24, 2002, will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Wendy R. Sanhai, Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3821; telephone: (301) 496–7736 ext. 244; facsimile: (301) 402–0220; e-mail: sanhaiw@od.nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent application.

SUPPLEMENTARY INFORMATION: This invention relates to the spatial and temporal control of exogenous gene expression in genetically engineered cells and organisms. In particular, it covers the use of heat inducible promoters such as the promoter of heat shock genes to control the expression of exogenous genes. It further relates to the use of focused ultrasound to heat cells that contain therapeutic genes under the control of heat shock promoter, thereby

inducing the expression of therapeutic genes.

The prospective exclusive license territory will be worldwide and will be royalty-bearing. Said license may be granted within sixty (60) days from the date of this published notice unless the NIH receives written evidence and argument establishing that granting this license is inconsistent with the terms and conditions of 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i).

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 17, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.
[FR Doc. 02-10117 Filed 4-24-02; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Synthetic Ordered Arrays of Antigen for the Induction of Autoantibodies

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the invention embodied in United States Patent Application 09/835,124 and its foreign equivalents, entitled "Virus-Like Particles for the Induction of Autoantibodies," filed on April 13, 2001, with priority back to U.S. S/N 60/105,132, filed October 21, 1998, to LigoCyte Pharmaceuticals, Inc., having a place of business in Bozeman, Montana. The patent rights in this invention have been assigned to the United States of America.

DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 24, 2002, will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Peter Soukas, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; e-mail: ps193c@nih.gov; telephone: (301) 496-7056, ext. 268; facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: This invention claims compositions and methods for producing antibodies to tolerogens (self-antigens normally exposed to B cells that fail to induce an antibody response). The compositions of the invention comprise multiple copies of a tolerogen (or at least one B cell epitope of a tolerogen) chimerized to capsomeric structures or capsid proteins in an orderly manner. This invention could potentially replace any treatment utilizing chronic administration of a monoclonal antibody that reacts with a self-antigen.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to non-Virus-Like Particle (VLP) polyvalent liposome nanoparticle vaccines against self-antigens.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 17, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.
[FR Doc. 02-10116 Filed 4-24-02; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Privacy Act of 1974: Establishment of New Privacy Act System of Records

AGENCY: Substance Abuse and Mental Health Services Administration (SAMHSA), DHHS.

ACTION: Privacy Act of 1974: Notice of new system of records

SUMMARY: The Substance abuse and mental Health Services Administration (SAMHSA) is establishing a new system of records in order to implement the provisions of the Controlled Substances Act as amended (21 U.S.C. 823(g)(2)).

SUPPLEMENTARY INFORMATION: New legislation permits practitioners to seek waivers from the separate registration requirements required under the Controlled Substances Act for practitioners who use narcotic treatment medications in the maintenance or detoxification treatment of opiate addiction. The Secretary of the Department of Health and Human Services has delegated to SAMHSA the responsibility of determining whether practitioners meet the requirements for these waivers. To be eligible for waivers, practitioners must be licensed physicians, must be registered by Drug Enforcement Administration (DEA), must fulfill qualifications for training and experience, and must make written certifications about treatment capacity and patent load. Practitioners determined eligible for a waiver, will receive a unique identification number from DEA, and will be eligible to prescribe certain approved opioid treatment medications.

This new system of records will permit SAMHSA to conduct its responsibilities to determine whether practitioners meet requirements for waivers. SMHSA will use the information from this system to verify DEA registration status, to verify medical license status, and to verify training and experience qualifications. In addition, for those practitioners who consent, SMHSA will use limited information from this system to augment the Substance Abuse Treatment Facility Locator. The Treatment Facility Locator is a web-based system that permits individuals seeking treatment to locate treatment providers.

DATES: SAMHSA invites interested persons to submit comments on the proposed new system on or before May 28, 2002. SAMHSA will adopt this new